Hybio Pharmaceutical Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Yu Pinxiang

Chief executive officer

CN¥1.8m

Total compensation

CEO salary percentage	n/a
CEO tenure	5.5yrs
CEO ownership	0.06%
Management average tenure	3.1yrs
Board average tenure	4.7yrs

Recent management updates

Recent updates

CEO

Yu Pinxiang (51 yo)

5.5yrs

Tenure

CN¥1,842,600

Compensation

Ms. Pinxiang Yu serves as Director of Hybio Pharmaceutical Co., Ltd. since May 31, 2019 and serves as its Executive President. She served as a Vice President of Production Department at Hybio Pharmaceutica...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yu Pinxiang	Executive President & Director	no data	CN¥1.84m	0.060% CN¥ 6.1m
Honghong Tu	VP, CFO & Accounting Supervisor	3.3yrs	CN¥649.80k	no data
Di Yang	VP, Secretary & Director	2.8yrs	CN¥781.00k	no data
Zhaohui Zeng	Vice President	3.3yrs	CN¥1.19m	no data
Min Zhang	Vice President	2.9yrs	CN¥616.50k	no data
Heng Quan	Vice President of Human Resource & Administration Department	no data	CN¥840.50k	no data
Yu Liu	Vice President of Marketing	no data	CN¥398.30k	no data

3.1yrs

Average Tenure

48yo

Average Age

Experienced Management: 300199's management team is considered experienced (3.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yu Pinxiang	Executive President & Director	5.5yrs	CN¥1.84m	0.060% CN¥ 6.1m
Di Yang	VP, Secretary & Director	4.6yrs	CN¥781.00k	no data
Lian Zhong	Independent Director	3.3yrs	CN¥60.00k	no data
Shaobin Zeng	Non-Independent Director	4.8yrs	CN¥65.70k	2.46% CN¥ 251.5m
Lu Yang	Member of Non-Employee Supervisory Board	2.9yrs	no data	no data
Qingyang Li	Chairman of Supervisory Board	5.5yrs	no data	no data
Yangming Tang	VP & Director	3.8yrs	CN¥976.90k	no data
Wenyan Hu	Independent Director	2.9yrs	CN¥120.00k	no data
Shaoqiang Zeng	Vice Chairman	15yrs	CN¥60.10k	8.15% CN¥ 833.6m
Shaogui Zeng	Chairman	15yrs	CN¥1.12m	12.41% CN¥ 1.3b
Lin Liang	Supervisor	no data	no data	no data

4.7yrs

Average Tenure

48yo

Average Age

Experienced Board: 300199's board of directors are considered experienced (4.7 years average tenure).

Hybio Pharmaceutical Management

Management criteria checks 3/4

Key information

Recent management updates

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.045 loss per share (vs CN¥0.15 loss in 3Q 2023)

Hybio Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.068 loss in 2Q 2023)

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: CN¥0.02 loss per share (vs CN¥0.02 profit in 1Q 2023)

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Hybio Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Hybio Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: CN¥0.15 loss per share (vs CN¥0.05 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.068 loss per share (vs CN¥0.049 loss in 2Q 2022)

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.02 (vs CN¥0.06 loss in 1Q 2022)

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.096 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.049 loss per share (vs CN¥0.058 loss in 2Q 2021)

Hybio Pharmaceutical Co., Ltd. (SZSE:300199) agreed to acquire 10.81% stake in Hybio Biotechnology (Dali) Co., Ltd. from Dazhong Transportation (Group) Co., Ltd. (SHSE:600611) for CNY 20 million.

First quarter 2022 earnings released: CN¥0.06 loss per share (vs CN¥0.026 profit in 1Q 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

First quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.025 in 1Q 2020)

Hybio Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥5.60

New 90-day low: CN¥6.66

New 90-day low: CN¥7.17

New 90-day low: CN¥7.43

Third quarter earnings released

Hybio Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 14, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age